Skip to content

The Effect of Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Postpartum Hemorrhage After Twin Cesarean

The Effect of Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Postpartum Hemorrhage After Twin Cesarean in Kosar Hospial , Qazvin

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250509065661N1
Enrollment
89
Registered
2025-07-03
Start date
2025-06-06
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Postpartum hemorrhage. Condition 2: Twin pregnancy. Postpartum hemorrhage Twin pregnancy

Interventions

Intervention 1: Intervention group: The size of the intervention group is 89 people.They will receive intravenous oxytocin 300 mL/minute along with 0.2 mg of methylergonovine intramuscularly. The manu

Sponsors

Research and technology Deputy of Qazvin Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Gestational age over 34 weeks Twin pregnancy Para 0-3

Exclusion criteria

Exclusion criteria: Patients with known preeclampsia, eclampsia, and hypertensive disease Patients with coagulation disorders History of receiving blood during pregnancy Patients with severe anemia (Hb 16 g/dL) Patients with known ischemic heart disease History of thromboembolism or vascular thrombosis during pregnancy HIV-infected patients Patients with placental anomalies such as placenta accreta Patients who have taken enoxaparin one week before surgery or aspirin 3 days before surgery

Design outcomes

Primary

MeasureTime frame
Amount of postpartum Hemrrhage. Timepoint: During and 24 hours after cesarean section. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShokoh Sadat Haji Seyed Abotorabi

Qazvin University of Medical Sciences

abotorabi4242@yahoo.com+98 28 3323 6374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026